Novartis Draws Out Its APPLAUSE

Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.    

applause

Novartis AG is drip-feeding data from its APPLAUSE-IgAN trial. The study, assessing the oral complement factor B inhibitor Fabhalta (iptacopan) in IgA nephropathy (IgAN), was toplined a success in October. Now the company has revealed the finding on one of the two co-primary endpoints, saying that Fabhalta-treated patients achieved a statistically significant (p<0.0001) reduction in proteinuria.

The data come from a pre-specified interim analysis comprising 250 patients for the efficacy analysis and 443 for the safety...

Welcome to Scrip

Create an account to read this article

More from Clinical Trials

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

More from R&D

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.